Gyre Therapeutics (GYRE) Receivables - Other (2012 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Receivables - Other of $230000.0 for Q1 2026, up 15.0% year-over-year from $200000.0 in Q1 2025, and up 15.0% quarter-over-quarter from $200000.0 in Q4 2025.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Receivables - Other (2012 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Receivables - Other for 7 consecutive years, with $230000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Other rose 15.0% year-over-year to $230000.0; the TTM figure through Mar 2026 stood at $230000.0 (up 15.0% YoY), while the FY2025 annual figure was $200000.0, down 95.97% from the prior year.
- Receivables - Other advanced to $230000.0 in Q1 2026 per GYRE's latest filing, from $200000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $5.0 million in Q4 2024 and bottomed at -$1.1 million in Q4 2023.
- Historically, Receivables - Other has averaged $814500.0 across 4 years, with a median of $265000.0 in 2023.
- Annual changes were most pronounced in 2024 — Receivables - Other jumped 549.37% — and 2025, when it plunged 95.97%.
- Gyre Therapeutics' Receivables - Other stood at -$1.1 million in 2023, then surged by 549.37% to $5.0 million in 2024, then slumped by 95.97% to $200000.0 in 2025, then grew by 15.0% to $230000.0 in 2026.
- Business Quant data shows GYRE's Receivables - Other at $230000.0 in Q1 2026, $200000.0 in Q4 2025, and $200000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 255,000.00 |
| Mar 31, 2026 | 230,000.00 |
| Dec 31, 2025 | 200,000.00 |
| Sep 30, 2025 | 230,000.00 |
| Jun 30, 2025 | 230,000.00 |
| Mar 31, 2025 | 230,000.00 |
| Dec 31, 2024 | 4.96 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | 1.30 Mn |
| Dec 31, 2023 | -1.10 Mn |
| Sep 30, 2023 | 1.20 Mn |
| Jun 30, 2023 | 300,000.00 |
| Dec 31, 2014 | 13,000.00 |
| Mar 31, 2014 | 64,000.00 |
| Dec 31, 2013 | 183,000.00 |
| Sep 30, 2013 | 32,000.00 |
| Mar 31, 2013 | -997,000.00 |
| Dec 31, 2012 | 1.05 Mn |